Patent 8940752 was granted and assigned to Incyte on January, 2015 by the United States Patent and Trademark Office.
The present invention provides pyrimidinones that modulate the activity of phosphoinositide 3-kinases (PI3Ks) and are useful in the treatment of diseases related to the activity of PI3Ks including, for example, inflammatory disorders, immune-based disorders, cancer, and other diseases.